Clinical trials: Stage I Skin Cancer
Bone Pain in Stage I - III Breast Cancer
NOLAN: Naproxen or Loratadine and Neulasta
The primary objective of the study is to estimate the difference in bone pain between breast cancer patients receiving chemotherapy and pegfilgrastim and either no prophylactic intervention, prophylactic naproxen, or prophylactic…
- Trial name
- NOLAN (NCT01712009)
- Testing
- Naproxen, Loratadine, Pegfilgrastim
- Where
- 83 sites in United States
- Volunteers
- 600 people
- Sponsor
- Amgen
Breast Cancer
3-Dimensional Conformal Radiation Therapy In Treating Women With Stage I or Stage II Breast Cancer Previously Treated With Lumpectomy and Axillary Node Dissection
RATIONALE: 3-dimensional conformal radiation therapy delivers a high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00068263
- Testing
- radiation therapy
- Where
- 2 sites in United States
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer
Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831
This research study is looking at tissue samples from women with breast cancer who were treated on clinical trial NCCTG-N9831. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more…
- Trial name
- NCT00898898
- Testing
- diagnostic laboratory biomarker analysis
- Volunteers
- 2,837 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
This phase I trial studies the side effects and best dose of rivogenlecleucel, and how well it works, in treating patients with blood cancer that has come back (recurrent) after stem cell transplant.
- Conditions
- Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm
- Trial name
- NCT03807063
- Testing
- Rivogenlecleucel, Rimiducid
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Breast Neoplasms
Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.
Study to determine the Maximum Tolerated dose of BIBW 2992 given in combination with Herceptin®
- Trial name
- NCT00950742
- Testing
- Trastuzumab, BIBW 2992
- Where
- 5 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer, Ductal Carcinoma
Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
The purpose of this research study is to see if a participant's nipple and areola can be safely preserved by adding radiation to these areas after a nipple-sparing mastectomy and immediate breast reconstruction.
- Trial name
- NCT01208974
- Testing
- Nipple-Sparing Mastectomy, Breast Reconstruction, Axillary Surgery
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Miami
Advanced Solid Tumor
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457
- Trial name
- NCT02189174
- Testing
- CLR457
- Where
- 7 sites in United States, Canada and 3 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Melanoma
A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)
This is a study to evaluate the safety and tolerability of peginterferon alfa-2b (PegIFN alfa-2b) as adjuvant treatment in Japanese participants with malignant melanoma after definitive surgical resection including complete…
- Trial name
- NCT01636960
- Testing
- PegIFN alfa-2b
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma
Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial
This phase I trial is to find out the best dose, possible benefits and/or side effects of NHS-IL12 given together with bintrafusp alfa and radiation therapy in treating patients with hormone receptor positive, HER2 negative…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic HER2 Negative Breast Adenocarcinoma
- Trial name
- NCT04756505
- Testing
- Bintrafusp Alfa, Immunocytokine NHS-IL12, Radiation Therapy
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma
Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)
Background: GC1008 is a genetically engineered antibody designed to block the activity of transforming growth factor-beta (TGF-beta).
- Trial name
- NCT00923169
- Testing
- Anti-Transforming Growth Factor-beta (GC 1008)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Adult Solid Neoplasm, Estrogen Receptor Negative
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of cilengitide when given together with paclitaxel weekly in treating patients with solid tumors that have spread nearby or to other areas of the body and cannot be…
- Conditions
- Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma
- Trial name
- NCT01276496
- Testing
- Cilengitide, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
The scope of this study is to measure the impact of MammaPrint on treatment in Hormone Receptor (HR)-positive HER2-negative breast cancer patients.
- Trial name
- IMPACt (NCT02670577)
- Where
- 17 sites in United States
- Volunteers
- 481 people
- Sponsor
- Agendia
Carcinoma Breast Stage IV
PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2
The main objective of this study is to determine the feasibility of the combination of the proteasome inhibitor bortezomib (PS-341, Velcade) with trastuzumab (Herceptin) and to determine the best dose of bortezomib to combine…
- Trial name
- NCT00199212
- Testing
- Combination of trastuzumab and PS-341
- Where
- Belgium
- Volunteers
- 19 people
- Sponsor
- Jules Bordet Institute
Breast Cancer, Invasive Breast Cancer
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
This study is investigational and is not designed to treat cancer. In other words, the study drug, entinostat, is not being given to treat cancer.
- Conditions
- Breast Cancer, Invasive Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer
- Trial name
- NCT03361800
- Testing
- Entinostat
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer Stage I
Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer
For patients with HER2-positive early-stage breast cancer, NCCN guidelines recommend chemotherapy plus targeted therapy as the standard adjuvant treatment for patients with tumors larger than 1 cm or lymph node-positive.
- Trial name
- NCT05861271
- Testing
- Capecitabine，Pyrotinib
- Where
- China
- Volunteers
- 1,008 people
- Sponsor
- Fudan University
NSCLC Stage IV, Melanoma Stage IV
Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma
Modulating the gut microbiome to improve response to immune-checkpoint inhibitors is an active area of study. Prebiotic substances (compounds which positively shift the gut microbiome) are a reliable and safe method of gut…
- Conditions
- NSCLC Stage IV, Melanoma Stage IV, Unresectable Melanoma, Advanced Non-Small Cell Lung Cancer
- Trial name
- NCT05303493
- Testing
- Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI
- Where
- 3 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
RBX7455 Before Surgery for the Treatment of Operable Breast Cancer
This clinical trial studies the side effects and possible benefits of RBX7455 given before surgery in treating patients with breast cancer that can be removed by surgery (operable).
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04139993
- Testing
- Microbiota-based Formulation RBX7455
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
This phase II trial studies the side effects and how well radiation therapy works in treating patients with stage 0-II breast cancer.
- Conditions
- Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7
- Trial name
- NCT01245712
- Testing
- Accelerated Partial Breast Irradiation, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Triple Negative Breast Cancer
Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer
This is the first part of a 2-part study assessing the efficacy of AZD2281 in combination with paclitaxel in 1st or 2nd line treatment of patients with metastatic triple negative breast cancer.
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT00707707
- Testing
- AZD2281, Paclitaxel
- Where
- 6 sites in Australia, Austria and 2 more
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Breast Cancer
Ductal Lavage in Assessing Women With Early Breast Cancer or at High Risk of Developing Breast Cancer and Who Are Eligible For Tamoxifen Therapy
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of or treat early cancer. Diagnostic procedures, such as ductal lavage, may improve the ability to assess the effectiveness of…
- Trial name
- NCT00083044
- Where
- 2 sites in United States
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.